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Epithelial tissue provides the body with its first layer of protection against
harmful environmental stimuli by enacting the regulatory interplay between
a physical barrier preventing the influx of external stimuli and an inflamma-
tory response to the infiltrating stimuli. Importantly, this interdependent
regulation occurs on different time scales: the tissue-level barrier per-
meability is regulated over the course of hours, whereas the cellular-level
enzymatic reactions leading to inflammation take place within minutes.
This multi-scale regulation is key to the epithelium’s function and its dys-
function leads to various diseases. This paper presents a mathematical
model of regulatory mechanisms in the epidermal epithelium that includes
processes on two different time scales at the cellular and tissue levels. We use
this model to investigate the essential regulatory interactions between epi-
dermal barrier integrity and skin inflammation and how their dysfunction
leads to atopic dermatitis (AD). Our model exhibits a structure of dual (posi-
tive and negative) control at both cellular and tissue levels. We also
determined how the variation induced by well-known risk factors for AD
can break the balance of the dual control. Our model analysis based on
time-scale separation suggests that each risk factor leads to qualitatively
different dynamic behaviours of different severity for AD, and that the
coincidence of multiple risk factors dramatically increases the fragility of
the epithelium’s function. The proposed mathematical framework should
also be applicable to other inflammatory diseases that have similar
time-scale separation and control architectures.1. Introduction
Most physiological processes are tightly controlled by regulatory interactions
across different temporal and spatial scales. An important example of such
multi-scale regulatory interactions is found in the epithelium, the tissue covering
the organs and cavities of animal bodies. The epithelium provides the first layer
of protection against harmful environmental stimuli, such as bacteria, chemicals
or pollen, through a tightly controlled interplay between the regulation of the
physical barrier permeability to the environmental stimuli and the immune reac-
tion to the infiltrating stimuli [1–4]. Importantly, while the regulation of the
physical barrier permeability results from the orchestration between growth,
differentiation and apoptosis of different cell types of the order of hours or
days [5,6], the phenotype of each cell within the epithelium is determined locally
based on the concentration of local effectors (such as enzymes and gene tran-
scripts) regulated through protein–protein interaction (PPI) networks of the
order of minutes [7,8]. In turn, the strength of the inter-epithelial stimulus
depends on epithelial permeability, a tissue-level property determined by the epi-
thelium’s homeostasis. Therefore, regulation of epithelium function involves an
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2interplay of fast inflammation-inducing PPIs with slow
barrier-reconfiguring processes in an archetypical example of
multiple-scale regulatory feedback.
Defects in this multi-scale feedback regulation may lead to
the loss of epithelial homeostasis, inflammation and the devel-
opment of diseases, including atopic diseases, such as
asthma [3], allergic rhinitis (hay fever) [9] and atopic dermatitis
(AD) [10]. These diseases are typically characterized by two
strongly interconnected symptoms (loss of barrier function
and exacerbated inflammatory reactions to environmental
stimuli) that occur at different spatio-temporal scales.
Epidemiological and biochemical studies have established
the relevance of a variety of risk factors that predispose indi-
viduals to atopic diseases, although the exact causes of these
diseases are not fully understood. Risk factors include genetic
polymorphisms, as well as environmental factors (such as
exposure to allergens or pollutants) [11–14]. However, the
role of individual risk factors in epithelial function is difficult
to pinpoint experimentally because of the complexity of the
highly interconnected, multi-scale epithelium regulatory net-
work. Indeed, loss of regulation triggered by a risk factor may
be the result of imbalances between different processes across
cellular and tissue levels. Furthermore, clinically relevant
studies are hampered by the interference between multiple
risk factors, often observed in patients with atopic dis-
eases [15]. This paper presents a mathematical framework
to analyse systems-level mechanisms for atopic diseases.
Our framework allows us to systematically assess the effects
of single or multiple risk factors on epithelium function;
study how the coincidence of multiple risk factors severely
increases the propensity to develop atopic diseases; and
deepen our understanding of the underlying mechanisms
that lead to pathological conditions.
Several mathematical models have been proposed for
studying the spatial dynamics of epithelial cells, including
migration, proliferation, differentiation and death of gut cells
in relation to colorectal cancer [16,17], or reorganization of
the epidermis during wound healing [18,19]. However, these
models do not explicitly consider the regulatory interplay
between the two defensive mechanisms of the epithelium,
although the skin barrier integrity and the inflammatory
response mediated by PPIs have been modelled in iso-
lation [20,21]. Our framework builds upon a mathematical
model of the cellular-level regulatory mechanisms leading to
AD that focuses on the activity of proteolytic enzyme kalli-
kreins (KLKs) responsible for both skin desquamation and
inflammation [22]. Although this cellular model successfully
captures key clinical features of AD and their dependence on
some risk factors, it does not consider the intertwined,
multi-scale feedback regulation across cellular and tissue levels.
This paper proposes an ordinary differential equation
(ODE) model of epithelium function that includes the essen-
tial regulatory interplay between the two protective
properties that operate on different time scales: physical
barrier integrity (on slow scales) and immune reactions to
eradicate the stimulus (on fast scales). We focus on the dis-
ruption of homeostasis in the epidermis leading to AD, an
archetypical example of atopic diseases that affects nearly
30 per cent of the paediatric population worldwide [14].
AD is characterized by an abnormal hypersensitivity to
environmental stimuli and a loss of skin barrier function
and is commonly manifested as dry, scaly skin and a rash.
Note, too, that the essential features of complex regulatorymechanisms clarified by our multi-scale model can be used
to broaden our understanding of other pathophysiological
processes related to the loss of epithelial homeostasis, par-
ticularly in asthma and hay fever, given the confirmed
association between AD and other atopic diseases [14].
Crucially, it is the slow, tissue-level behaviour that is
observable and used for treatment in clinical settings, yet
such long-term dynamics are intricately interlinked with the
fast, cellular PPIs. To study the slow dynamics, we assume
a separation of time scales and consider quasi-stationarity
at the cellular level, leading to a system of differential–
algebraic equations. Our model (figure 1) is constructed based
on the view that overall homeostasis is achieved by mainly
two types of regulated balance: one between activation and
inhibition of KLKs at the cellular level and another between
positive and negative feedbacks from inflammation-inducing
signalling pathways to the strength of stimulus at the tissue
level. The interplay between the fast cellular-level reac-
tions [22] and the much slower tissue-level dynamics
controlling the concentration of the inter-epidermal stimulus
is needed in order to understand AD as being a result of the
disruption of epithelium homeostasis: excessive skin desqua-
mation weakens the skin barrier, allowing more stimulus to
penetrate and trigger PPIs that result in immune reactions
capable of eradicating the stimulus and also lead to inflam-
mation (figure 1a). Furthermore, our model allows us to
identify particular terms and parameters that disrupt these
balances at the cellular and tissue levels, which naturally
correspond to well-known AD risk factors.
Our model reproduces several key clinical features of AD.
In particular, it clarifies the relationship between risk factors
and specific dynamical responses to external stimuli. The
model also predicts, in a quantitative manner, the increase
in the susceptibility of the epidermis to developing atopic
conditions given multiple risk factors. These results contrib-
ute to the identification of the key underlying regulatory
interplay between skin barrier homeostasis and inflammation
in AD, and may lead to a more accurate characterization of
the disease symptoms required for personalized treatment.
Moreover, our modelling approach, based on the time-scale
separation and the view that the disease occurs as a result
of loss of balance between dual (positive and negative) feed-
backs, provides a theoretical framework for the study of
multi-scale regulatory interactions in many other physiologi-
cal systems. We discuss the generality of our modelling
approach for studying the regulatory interactions between
the cellular-level inflammatory response and tissue-level
regulation of epithelial homeostasis.2. Multi-scale model for atopic dermatitis
Our multi-scale model of epidermal homeostasis builds upon
a recent cellular-level model for regulation of KLK activi-
ties [22], which we couple to a model of tissue-level
regulation. The input and output of the cellular-level model
are the stimulus and the resultant inflammation, respectively,
which, in turn, become the output and input of the tissue-
level model (figure 1c). The biological processes considered
in the multi-scale model are explained below, while a complete
model description, together with the nominal parameters used
in the simulation, is found in appendix A. The corresponding
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Figure 1. Multi-scale model of AD. (a) Tissue-level reactions considered. (a) Skin desquamation by KLK* (active KLK), (b) inhibition of LB lipid release by PAR2*
(active PAR2), (c) PAR2 activation by KLK* (at the cellular level), (d) penetration of the environmental stimuli into the inner layers of the epidermis, (e) inflammation
triggered by PAR2* (at the cellular level), ( f ) eradication of stimuli by immune reactions, and (g) protection against environmental stimuli by healthy skin barrier.
(b) Cellular-level reactions considered. (a) Release of inactive KLK and its inhibitor LEKTI enhanced by inter-epidermal stimulus, (b) auto-activation of KLK by pro-
teolysis, (c) inhibition of KLK* by LEKTI, (d) activation of PAR2 by KLK*, leading to inflammation, and (e) increased release of KLK and LEKTI upon PAR2 activation.
(c) Schematic representation of the multi-scale model for epidermal function, consisting of the tissue-level regulation for skin barrier integrity (beige circle) and the
cellular-level PPI leading to inflammation (violet circle). (d ) Core structure of our model and the risk factors. Switch behaviour of inflammation occurs through
stimulus-induced PPI at the cellular level (violet circle) mediated by a combination of positive (KLK* activation) and negative (KLK* inhibition by LEKTI) controls.
The concentration of the inter-epidermal stimulus is controlled at the tissue level (beige circle) by a combination of positive (via skin barrier permeability) and
negative (via stimulus eradication) feedbacks from KLK*-activated PAR2* leading to inflammation. We consider four risk factors for AD, ‘high pH’, ‘low LEKTI’, ‘high
permeability’ and ‘weak stimulus eradication’, each of which breaks the balanced control at the cellular and tissue levels.
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3processes in the model (figure 1a) are indicated by the same
labels (a)–(f) in figure 1c.2.1. Modelling the tissue-level processes
Healthy skin with high barrier integrity prevents exacerbated
penetration of environmental stimuli into the inner epidermal
layers (figure 1a(g)) [23]. Our model considers the skin barrier
integrity determined by a combination of the amount of cor-
neocytes [24], their cohesion [25] and the lipid content [1] in
the skin barrier. Accordingly, high barrier integrity is preserved
by an appropriate balance between the production and desqua-
mation rates of corneocytes and by maintenance of high lipid
content. Skin barrier integrity is weakened as a result ofcellular-level responses. Excessive activation of KLKs leads to
increased skin barrier desquamation by degrading the inter-
cellular junctions (figure 1a(a)) [24], while activation of
protease-activated receptor 2 (PAR2) by active KLKs
(figure 1a(c)) leads to enhanced inhibition of the lamellar
body lipid release into the skin barrier (figure 1a(b)) [5]. Upon
disruption, the skin barrier triggers self-restoring mechanisms,
in the forms of gene expression, lipid release and transition
of terminally differentiated keratinocytes to corneocytes [1,5,6].
A defective skin barrier with low barrier integrity allows
more exogenous stimuli to invade the inner epidermal layers
(figure 1a(d)), forming a positive feedback loop from active
KLK and PAR2 (denoted by KLK and PAR2 hereafter) to the
stimulus concentration. For the inflammatory states, a large
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Figure 2. Cellular-level switch-like behaviour. Adapted from Tanaka et al.
[22]. (a) Dose– response behaviour of PAR2 (inflammation) represented
by bistability in the bifurcation diagram with varying concentrations of stimu-
lus. The inflammation is on the low branch (no inflammation) until the
stimulus increases to the inflammatory threshold Sþ, at which point the
inflammation switches to the high branch and persists until the stimulus
falls below the recovery threshold S2. (b) Cellular-level risk factors increase
the severity of inflammation compared with the healthy condition (black).
‘Low LEKTI’ (blue) decreases Sþ, increasing the sensitivity to the stimulus.
‘High pH’ (red) decreases S2, resulting in more sustained inflammation.
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4amount of PAR2 is induced and internalized, which then trans-
duces stronger canonical signalling cascades and increases the
expression of pro-inflammatory genes (figure 1a(e)) [26]. The
inflammatory level in our model is accordingly represented
by the level of PAR2. These signalling cascades also trigger
PAR2-mediated immune reactions which persist even after
the inactivation of PAR2 [27]. PAR2-induced immune
reactions eradicate the accumulated stimulus in the inner epider-
mal layers (figure 1a(f)) bymediating the release of antimicrobial
peptides or the induction of keratinocyte phagocytosis [1,28],
forming a negative feedback loop from PAR2 to the stimulus
concentration. The concentration of stimulus that penetrates
the inner epidermal layers is thus determined by the balance
between the positive and negative feedback regulations, whose
strengths, respectively, depend on the skin permeability and
the capacity of stimulus eradication (figure 1d).
The activities of the KLKs are regulated by the cellular-level
PPI network (figure 1b), which is induced by the internalized
stimulus, as modelled by Tanaka et al. [22]. Ourmodel considers
infiltrated stimuli, such as Staphylococcus aureus, which promote
the production of KLK via the activation of pattern-recognition
receptors [29,30]. Stimulus-triggered release of KLK and its
inhibitor LEKTI into the extracellular space (figure 1b(a)) is fol-
lowed by auto-activation of KLKs (figure 1b(b)), inhibition of
KLK by LEKTI (figure 1b(c)), and activation of PAR2 through
KLK by proteolysis (figure 1b(d)). All of these protein inter-
actions occur in a pH-dependent manner. The model also
includes positive feedback from PAR2 to the expression of
KLKs and LEKTI (figure 1b(e)). The activities of the KLKs are
thus determined by the balance between their activation and
inhibition rates (figure 1d).
We represent this multi-scale system of regulatory inter-
actions as a system of integral–differential equations with the
time-scale separation by assuming that the steady states of
the cellular-level enzymatic reactions (attained in seconds to
minutes [31]) affect the tissue-level changes in the skin barrier
(in hours after perturbation by the external stimulus [5]).2.2. Modelling the effects of risk factors for atopic
dermatitis
We consider four risk factors that break the balanced regu-
lation at each level, that is, the balance between the
activation and inhibition of KLK at the cellular level and
the balance between the positive and negative feedback con-
trols at the tissue level. They correspond to the following
four main genetic and environmental elements known to
predispose persons to AD.
High pH. Increased pH in the epidermis (pH around 6.5 in
AD patients compared with 4.5 in healthy skin) leads to
increased catalytic activity of KLKs [8,24].
Low LEKTI. A decrease in the basal expression rate of
LEKTI, a KLK inhibitor, leads to compromised inhibition
of KLK activity [12].
High permeability. Increased skin barrier permeability, for
example by a genetically determined decrease in the
expression of filaggrin (an essential protein for maintaining
strong cohesion between epithelial cells) [25], allows
increased penetration of stimulus, leading to strong posi-
tive feedback from PAR2 and KLK to the stimulus
concentration. It is modelled with increased nominal skinpermeability, P˜, which corresponds to the permeability of
the unaffected skin.
Weak stimulus eradication. Decreased capacity of the immune
reactions to eliminate the infiltrating stimuli [32,33] leads
to compromised negative feedback from PAR2 to the
stimulus concentration.
We investigate the effects of the risk factors (in isolation
and combination) on the development of AD by altering
the corresponding parameters in the model. The parameters
corresponding to the cellular-level risk factors, ‘high pH’
and ‘low LEKTI’, are taken from Tanaka et al. [22]. New par-
ameters corresponding to the tissue-level risk factors, ‘high
permeability’ and ‘weak stimulus eradication’, are varied to
see the effects of the balance between the positive and
negative feedbacks on the development of AD.3. Bistable switch with hysteresis at the cellular
level
We are interested in the steady states of PAR2 and KLK
(denoted hereafter as ½PAR2s and ½KLKs, with the sub-
script s indicating steady states), since we assume that
½PAR2s and ½KLKs are reached quickly compared with
the overall tissue dynamics which they affect.
Figure 2a shows the bifurcation diagram for PAR2
(inflammation) described by Tanaka et al. [22] with the inter-
epidermal stimulus concentration as a bifurcation parameter.
This dose–response curve exhibits bistability, with low and
high branches corresponding to the non-inflamed and inflamed
states, respectively. Therefore, the state switches to the high
branch when the stimulus increases above the inflammation
threshold Sþ and remains there until the stimulus decreases
below the recovery threshold S , Sþ, at which point it goes
back to the low branch and the inflammation stops. This clas-
sic hysteretic behaviour induced by the bistability of the model
captures the characteristic features of AD, namely the outbreak
and persistence of inflammation [22]. We note that similar bist-
ability and hysteresis is observed for ½KLKs with the same Sþ
and S2 values as for ½PAR2s.
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5The effects of two risk factors, low LEKTI and high pH,
on the development of AD have been investigated by
Tanaka et al. [22], and they are in good agreement with clini-
cal data from AD patients. Both risk factors increase the
severity of the inflammation (figure 2b) but in different
ways: a low LEKTI condition (blue) results in a lower Sþ, cor-
responding to more susceptibility to the stimulus, as it
requires less stimuli for inflammation to occur. A high pH
condition (red) leads to a more persistent inflammation
with lower S2, as it requires a further decrease in the stimuli
for the inflammation to stop.(c)
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Figure 3. Three qualitative dynamic behaviours of skin barrier integrity after
environmental challenges. (a) Homeostasis: observed when the stimulus is
decreased to S2 and the inflammation stops. (b) Oscillation: observed
when the stimulus is repeatedly decreased to S2 (inflammation stops)
and then re-increased to Sþ (inflammation recurs). (c) Persistent damage:
observed when the stimulus fails to decrease to S2.
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Focus
3:201200904. Dynamical behaviours in the multi-scale
model
This section presents a numerical characterization of the slow,
tissue-level dynamical behaviour of the full system in response
to external stimuli, especially the dynamical behaviour of the
skin barrier integrity, B, and the inter-epidermal stimulus con-
centration, S, which was a bifurcation parameter in the
previous section. They both depend on ½PAR2s and ½KLKs
(figure 1c, equation (A 1)). The skin barrier integrity is a clinically
relevant variable as an indicator of epidermis health and can be
measured by non-invasive methods. We can also follow the
dynamic behaviour of PAR2-mediated inflammation, which is
induced when the barrier is damaged and ceases when the
barrier starts to recover in the absence of PAR2.
All the simulations presented below correspond to the
response of the system to an external stimulus in sufficiently
large concentration such that S rises above the inflammation
threshold Sþ, moving the system onto the high branch in the
bifurcation diagram for both cellular-level risk factors with a
nominal barrier permeability (figure 2b).
4.1. Classification of dynamical behaviours in the slow
time
For different sets of parameters, our model exhibits three
qualitatively different dynamic behaviours for the skin
barrier integrity when responding to environmental chal-
lenges of the stimulus (figure 3), in order of increasing
severity of the AD manifestation:
Homeostasis. Complete recovery to the homeostatic level,
typical for a healthy epidermis,
Oscillation. Periodic loss of homeostasis, often found in
moderate AD skin, and
Persistent damage. Incapability of recovery to the homeo-
static level, often observed in severe AD skin.
These three behaviours can be understood in terms of the
interplay between the slow and fast dynamics leading to a
quasi-static sweep of the bifurcation curve of the fast system.
In the case of homeostasis, the stimulus S is eradicated via
immune reactions and falls below the recovery threshold S2,
at which point the inflammation stops as it jumps to the low
branch (figure 3a(ii)). The barrier integrity then recovers to its
homeostatic value with no inflammation (figure 3a(i)). This
behaviour is observed when the stimulus eradication is
strong enough to decrease S below S2 through negative feed-
back, although the skin barrier suffers from transient damagewhile the inflammation is on the high branch, leading to the
increase in S through positive feedback.
In some cases, however, S can increase again to Sþ after it
transiently falls below S2, thus re-triggering inflammation
that again decreases S below S2 through the same mechan-
ism. This cycle leads to an oscillation of the skin barrier
integrity (figure 3b). Whether S re-increases to Sþ or not is
determined by its steady-state concentration, Ss, when the
inflammation is on the low branch (no inflammation). If Ss
is higher than Sþ, then S eventually exceeds Sþ. A high Ss
reflects a weak barrier which cannot keep S low enough with-
out the inflammation causing negative feedback on S.
Under other conditions, S cannot be decreased below S2;
for example, when the stimulus eradication is not strong
enough (weak negative feedback) or when the barrier per-
meability is too high (strong positive feedback; figure 3c).
Such conditions lead to persistent damage of the skin barrier
integrity with the complete loss of barrier integrity, as the
inflammation cannot be resolved.
In addition to the qualitative nature of the dynamical behav-
iour, the severity of the transient barrier damage can be
quantitatively evaluated in terms of two clinically relevant
measures: the recovery time required for the barrier integrity
to recover to its homeostatic level and the maximum amplitude
of the damage to the skin barrier. These two measures are
usually not independent: themaximumamplitude of the barrier
damage depends on the recovery time, since the longer the
recovery takes, the heavier the damage is to the barrier.
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Figure 4. Effects of risk factors. (a) Effects of single risk factors on the cel-
lular-level bifurcation diagram. ‘High pH’ decreases S2 and ‘weak stimulus
eradication’ prevents the decrease of S, resulting in difficulty in lowering S
below S2. ‘Low LEKTI’ decreases Sþ and ‘high permeability’ increases S,
facilitating S to go above Sþ. An increase of S by ‘high permeability’
makes it more difficult to reach S2. (b) Risk factor-dependent behaviour
of barrier integrity. While healthy (black) shows homeostasis, ‘high pH’
(red) leads to persistent damage, whereas ‘low LEKTI’ (blue) results in
oscillation. The effects of the tissue-level risk factors are shown in figure 5.
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64.2. Risk factor dependence of dynamical behaviours in
the slow time
Our model predicts the risk factor dependence of the
observed behaviour for the skin barrier integrity classified
above, based on the different effects of each risk factor on
the tissue-level dynamics of S, the value of Ss, which is a sol-
ution of the multi-scale model, and the threshold values Sþ
and S2 determined by the cellular-level PPI (figure 4a).
Since the low LEKTI condition leads to a decrease in the
inflammatory threshold Sþ (figure 2b, blue), S is more likely
to increase to Sþ after it transiently decreases below S2, thereby
leading to an oscillation of the epidermal integrity (figure 4b,
blue). The high pH condition with a lower recovery threshold
S2 (figure 2b, red) leads to persistent damage (figure 4b, red),
because it is more difficult to decrease S below S2.
The high permeability increases S by allowing more of the
external stimulus to penetrate (figure 4a). The larger S is, the
more easily Sþ is reached, leading to the oscillation, and the
more difficult S is decreased to S2, leading to the persistent
damage. Increasing the degree of the high permeability risk
factor (figure 5a, blue arrow) leads to a qualitative transition
from homeostasis (green) to oscillation (yellow), and further
to persistent damage (red). This transition is accompanied by
a continuous increase in the maximum amplitude of the barrier
damage. Note that the external stimulus does not penetrate
enough to induce the inflammatory response (‘non-responsive’)
if the permeability is very low (figure 5a, grey).
When the capacity of stimulus eradication is weak, S cannot
be decreased even with high inflammation (figure 4a). Decreas-
ing the capacity of stimulus eradication (figure 5a, pink arrow)
results in a qualitative transition from homeostasis (green) to
persistent damage (red) directly, with a continuous increase in
the maximum amplitude of barrier damage. Weakening the
stimulus eradication capacity by itself does not lead to the
onset of oscillation, since it does not affect either of the two
oscillation-determining factors, i.e. Ss (determined by the
non-inflamed state) or Sþ (determined by the cellular-level PPI).
Our quantitative analysis of the proposed model suggests
that the severity of the (transient) damage to the skin barrier issignificantly increasedby the concurrenceofmultiple risk factors,
as is often the case for AD [11,25,34]. Concurrence of the two
tissue-level risk factors (‘high permeability’ and ‘weak eradica-
tion’) makes the transition from homeostasis to oscillation and
persistent damage occur by a smaller increase in the degree of
each risk factor, resulting in more frequent occurrences of oscil-
lation and persistent damage with a larger maximum
amplitude of barrier damage (figure 5a, grey arrow). Additional
presence of cellular-level risk factors (‘low LEKTI’, figure 5b, or
‘high pH’, figure 5c) further increases the skin vulnerability,
with a lower occurrence of ‘non-responsive’ (grey) and ‘homeo-
stasis’ (green) and a higher proclivity towards ‘oscillation’
(yellow) and ‘persistent damage’ (red) with a larger maximum
amplitude of barrier damage.5. Discussion
5.1. The regulatory structure of the model leads to
distinct dynamic signatures for different risk factors
We have proposed a multi-scale model of the epidermis as a
means to investigate the regulatory interplay between the
tissue-level skin barrier integrity and cellular-level inflam-
mation with an intrinsic separation of time scales. As a result
of a combination of the cellular-level switching and the
tissue-level feedback control (figure 1d), our model displays
three qualitatively different dynamic responses for skin barrier
integrity: homeostasis, oscillations and persistent damage
(figure 3). These behaviours emerge from a combination of
balanced feedback regulation at the cellular and tissue levels.
Our multi-scale model allowed us to assess the impact of
several risk factors on the epidermal function and suggests
that each risk factor has its own specific dynamic signature
(figure 5). These features could be used to characterize
patient-specific causes of AD from the observed dynamic
behaviours of the epidermis and to improve the personalized
treatment of AD. Importantly, the risk factor-dependent
qualitative behaviours do not depend on the particular
choice of system parameters, but rather on the general struc-
ture of the multi-scale regulatory network model and how
the different terms are affected by the risk factors. The
PAR2-induced inflammation is regulated by a dual (positive
and negative) control at the cellular level: negative control
with inhibition of KLK by LEKTI and positive control with
pH-dependent activation of KLK and PAR2. The concen-
tration of stimulus at the tissue level is also controlled in a
dual way: negative control to decrease it through its eradica-
tion and positive control to increase it by degrading the skin
barrier. A balance between the two dual controls acting at the
cellular and tissue levels is essential to maintaining the
healthy homeostasis. The risk factors in this paper corre-
spond to disturbed feedback strengths that cause an
imbalance of the dual control (figure 1d ), leading to either
oscillatory or persistent loss of homeostasis. The concurrence
of multiple risk factors, each of which affects the dual control,
dramatically increases the fragility of the regulatory system of
epithelial function, even if the system is robust enough to
buffer out disturbances caused by single risk factors.
5.2. Applicability to other inflammatory diseases
One of the main features of our model is the presence of a
switch at the cellular level realized by the bistability in the
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Figure 5. Increase in skin vulnerability caused by the presence of multiple risk factors. The figure presents a summary of the bifurcations and dynamical behaviours
observed for different combinations of tissue-level risk factors (‘high permeability’ and ‘weak stimulation eradication’) for (a) healthy (high LEKTI and low pH),
(b) low LEKTI and (c) high pH conditions. The black, blue and red circles in (a), (b) and (c), respectively, correspond to the nominal values used for the simulation
in figure 4b. Increase in AD severity is represented (i) by transition of the dynamical behaviours of the epidermal integrity from homeostasis (green) to oscillations
(yellow) and further to persistent damage (red) accompanied (ii) by increases in the maximum amplitude of the skin damage. The grey area indicates ‘non-
responsive’ owing to the strong skin barrier integrity. (a) Increasing permeability (blue arrow) leads to a qualitative transition from homeostasis to oscillation,
and further to persistent damage, accompanied by a continuous increase in the maximum amplitude. Decreasing the capacity of stimulus eradication (pink arrow)
results in a direct transition from homeostasis to persistent damage. Concurrence of the two tissue-level risk factors accelerates this transition (grey arrow). Additional
presence of cellular-level risk factors (‘low LEKTI’ (b) or ‘high pH’ (c)) increases the skin vulnerability with a smaller region of ‘non-responsive’ and ‘homeostasis’ but
with a larger region of ‘oscillation’ and ‘persistent damage’, compared with healthy (a).
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7bifurcation diagram of the inflammation (figure 2a), coupled
with a slower regulatory system. This structure makes our
model resemble an ‘on–off’ hybrid system [35], in which
switching between two dynamic control regimes (depending
on whether the inflammation is ‘on’ or ‘off’) determines the
global behaviour of the system.
Pathogen-induced signalling cascades play a key role in pro-
tecting the body from infection by triggering immune reactions
that contribute to theeradicationof the stimulus.However, these
signalling cascades also trigger tissue-damaging inflammation,
since the induction of stimulus-eradicating mechanisms often
concurs with the release of pro-inflammatory mediators
[36–38]. The switchmechanism prevents unnecessary and inef-
ficient immune reactions to be triggered, since the activation of
the signalling cascades occurs only when the stimulus concen-
tration is high enough (above the inflammation threshold) to
endanger the tissue, and the immune reactions persist until the
stimulus falls significantly below the inflammation threshold.
This ensures that inflammation does not recur through
random fluctuations of the stimulus concentration.
Unnecessary and ineffective immune reactions are
accompanied by inflammation that can cause the destruction
of tissues and has a significant impact on the epithelial function
by affecting the morphology [4,28], composition [39], abun-
dance [40] and micro-environment [1] of epithelial cells,
without contributing to eradicating pathogens [41,42]. Indeed,
this constitutes a major part of pathology in many inflammatory
and infectious conditions, including AD [41–43]. Therefore, fast
resolution of the inflammation is essential for the restoration of
homeostasis, and relies on abalancebetweennegative (via stimu-
lus eradication) and positive (via tissue damage) feedback from
the inflammation to the stimulus concentration.The bistability of the cellular-level inflammatory responses
together with the dual feedback on a longer time scale consti-
tute a biologically reasonable architecture in terms of efficiency
and robustness, and it has been found in many inflammation-
inducing PPI networks [44,45]. For example, bistability has
been found in the multi-scale regulatory networks of the
inflammatory response induced by cytokine interleukin 1
(IL1), another system of interest as regards AD [13,46]. This
system is similar in structure to the KLK system discussed in
this paper, since PPI leading to IL1 activation is also triggered
by stimuli that infiltrate through the skin barrier [47], including
several biotic and abiotic allergens [38,48], and active IL1
affects the stimulus concentration by initiating immune reac-
tions that eliminate the stimulus [38] and by altering skin
barrier formation [49]. Our model can also be applied to the
other two atopic diseases, asthma and hay fever, since the
regulation of bronchial and nasal epithelium function occurs
though a similar interplay between the tissue-level barrier
and cellular-level inflammatory response in the epidermis,
bronchial epithelium and nasal epithelium [9,14].5.3. Clinical significance
Despite its clinical importance, the epidermal function has
seldom been studied from a systems-level perspective. Con-
ventional experimental approaches have not fully revealed
the relationships between the barrier dysfunction and inflam-
matory response in the development of AD [33,50]. Our
model provides a platform to analyse the bi-directional inter-
play between skin barrier dysfunction and aberrant
inflammatory response (figure 1d ).
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8Our model suggests that the measurement of the barrier
integrity over time can predict the type of clinical course a
particular patient is expected to follow (figure 3). This is
also compatible with clinical findings: the long-term progno-
sis of atopic patients may be related to the type of behaviour
observed; whereas persistent inflammation is associated with
a poor prognosis, patients with periodic inflammation have a
better chance for resolution of the disease, indicating that
there may be a correspondence between these behaviours
and increasing severities of atopic diseases [51].
An empirical validation of our model predictions, particu-
larly the association between the four risk factors and dynamic
model behaviours (figure 5), and implementing the prediction
in dermatological practice will require an empirical system-level
investigation of the epithelium to measure the barrier integrity
and inflammation over time for different phenotypes and
environmental conditions. For this purpose, it is essential to
develop a newway to continuouslymeasure the barrier integrity
over several hours to a day; for example, by non-invasive
measurement of transepidermal water loss and skin hydration
measurements in AD patients [52] or by use of organotypic
cultures, which allow temporal and spatial quantitative charac-
terization of the skin [53]. Validation of our results through
such studies will contribute to a more efficient, patient-specific
treatment of AD and other atopic diseases, since the risk factor
triggering the disease condition in a particular patient can be
deduced from the time course of the barrier integrity.5.4. Possible extensions of the model and future work
Our model considers the essential processes and reactions that
contribute to the regulatory interplay between tissue- and cellu-
lar-level dynamics at different time scales from the viewpoint of
dual controls. This framework could be extended to include
another level with an even slower time scale corresponding to
the proliferation and differentiation of epithelial cells. The regen-
eration of the skin barrier requires skin barrier precursors, i.e.
correctly differentiated cells at the lower layers of the epi-
thelium [54]. Our model assumes a constant concentration bpre
of skin barrier precursors. However, formation of these barrier
precursors is in fact a dynamic process that is orchestrated
among differentiation, proliferation and apoptosis of epithelial
cells, and is further affected by inflammatory signals [49,55].
Describing such dynamics of the epithelial cells at an even
slower time scale and coupling it to the multi-scale model pro-
posed here would allow us to explore the interplay between
inflammation and epithelial tissue renewal, and to address inter-
esting, open questions regarding deregulation of epithelium
renewal in the context of inflammation,whichplays an important
role not only for AD [54] but also for the development of
tumours [56].
The skin immune system can interact with the systemic
immune system in AD, which may be incorporated into the
model in the future. It has been widely observed that AD
patients are more prone to develop asthma and hay fever,
leading to the so-called atopic march [14,57]. It is thought
that allergic reactions occur in different organs owing to aller-
gic sensitization, which is the induction of allergic reaction and
the establishment of immunological memory by repeated
exposure of inter-epithelial cells to antigen [14]. This sensitiz-
ation usually occurs at the systemic level, and the exposure to
the allergen in other organs, after the establishment of sensit-
ization in the skin, can initiate allergic reactions andsubsequent immunopathology there, although local factors
such as the integrity of epithelium may also be important
for the development of allergic diseases [58]. Incorporation
of the allergic reaction in the model would allow us to explore
not only the mechanisms of the atopic march but also the
allergic diseases of strong clinical relevance [59,60], while
our model considers early events in the pathogenesis of AD
that occur before adaptive immune responses to the stimuli,
such as histamine release by primed mast cells, are initiated.
5.5. Concluding remarks
We proposed a multi-scale model for epithelial function which
predicts that the underlying risk factors for AD can be inferred
from the clinically observable dynamic response of the skin
barrier to environmental challenges. Our model analysis using
time-scale separation reveals the effects of AD risk factors on
the epidermal function regulated by the dynamic interplay
between inflammation and skin barrier permeability. Our results
may lead to a better understanding of the design principles of the
regulatory systems for epithelial homeostasis and inflammation
and may be able to be extrapolated to other atopic diseases.
Our modelling approach provides a theoretical framework for
studying multi-scale regulatory interactions, characteristic of
nearly all physiological systems.
Atopic diseases represent an important and unresolved
health problem, mainly because their causes have not yet been
elucidated owing to the complex nature of the underlying regu-
latory networks across different scales. Clinical research will
benefit from our systems-level mathematical framework for
studying epithelium function, as it will allow systematic evalu-
ations of the effects of risk factors and different treatments,
such as corticosteroids or emollients, on clinically observable epi-
theliummarkers such as the barrier function. We expect that our
research will contribute to a deeper understanding, more accu-
rate description and patient-specific treatment of atopic diseases.
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G020434/1. R.J.T. acknowledges funding from the EPSRC through
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A.1. Multi-scale kallikrein model description
Our multi-scale model is a combination of the cellular-level
model proposed by Tanaka et al. [22] (model 1 with positive
feedback from ½PAR2 to LEKTI production) and a tissue-
level model described as
dS
dt
¼ Sout
~P
Bþ 1 S ð fIP IP þ I0Þ ðA1aÞ
and
dB
dt
¼ bpre
1þ kL½PAR2s
1 B
~B
 
 dK½KLKsB; ðA2bÞ
where t corresponds to the slow time scale, S is the concentration
of the inter-epidermal stimulus and B is the barrier integrity.
The inter-epidermal stimulus, S, increases by the penetration
of external stimulus,Sout, through thebarrier, hence its rate is pro-
portional to Sout and inversely proportional to the skin barrier
Table 1. Deﬁnitions of systems parameters and their nominal values used
for the simulations.
parameter description
nominal
value
Sout concentration of external
stimulus
95
P˜ nominal skin permeability 0.4
fIP strength of stimulus eradication
by PAR2*-mediated immune
reactions
0.8
I0 PAR2*-independent immune
reactions
1
bpre concentration of skin barrier
precursors
0.5
kL strength of lipid release
inhibition by PAR2*
10
B˜ nominal skin barrier integrity 1
dK rate of desquamation by KLK* 0.1
1 minimum barrier integrity 0.01
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9integrity, B (figure 1c(d)). The minimum barrier integrity, 1,
reflects the fact that even very severe cases of AD [61] do not
lead to a complete destruction of the skin barrier and ensures
that the model is always well defined. Eradication of S occurs
by the combination of PAR2-independent (I0) and -dependent
(IP) immune reactions (figure 1c(f)) represented by
IP ¼
ðt
0
½PAR2s etþx dx; ðA3Þ
where the convolution with a decaying exponential captures the
persistence of the immune reactions even after inactivation of
PAR2 [27].
Thebarrier integrity,B, is determinedby thebalance between
the production and degradation of the barrier. The barrier is pro-
duced from precursors, which are assumed to be constantly
available with a fixed concentration, bpre, and lipids, whose
release is inhibited by PAR2 (figure 1c(b)). The capacity of the
barrier to self-restore the nominal barrier integrity, B˜, following
its disruption [1,6] is represented by a logistic term. The degra-
dation of the barrier occurs as a result of desquamation
mediated by KLK (figure 1c(a)).
Note that ½PAR2s and ½KLKs are the stable steady-state
concentrations of PAR2 and KLK obtained from the ODE
model [22] for the cellular-level PPI reaction network which
describes the dynamic behaviour of the concentration of six
species, including PAR2 and KLK, as a six-dimensional
system of ODEs with 21 parameters.A.2. Parameter values and robustness of the model
outcomes
Thenominal values of the parameters for the cellular-levelmodel
are taken from Tanaka et al. [22]. For the tissue-level model, we
chose nominal values (table 1) that are consistent with available
experimental data. Since the experimental data to date are quali-
tative rather than quantitative, our model predictions are
concerned with the qualitative effects of the risk factors, in
terms of a loss of balance of the dual control, on the system’s
behaviour.
Such results are largely robust to the parameter choices, as
confirmed by a detailed analysis of the sensitivity of the par-
ameters on the model behaviours. Our numerics show that the
qualitative behaviour is preserved when the parameters are
changed 10–100-fold.More specifically, the PAR2-independent
immune reactions (I0) and the nominal skin barrier integrity (B˜)
are scaling factors for Ss. The concentration of skin barrier precur-
sors (bpre) affects the skin barrier recovery time, but does not alter
the qualitative behaviours. The strength of lipid release inhibition
by PAR2 (kL) and the rate of desquamation by KLK
 (dK) scale
the concentrations of ½KLKs and ½PAR2s, thus affecting thepropensity for persistent loss of homeostasis but not the
qualitative behaviours.
The other two parameters of the model encapsulate the
effects of particular risk factors. The skin permeability (P˜)
was varied from ~P  0 (no influx of the stimulus) to P˜ ¼ 1
(100% permeable barrier) to assess the effects of the ‘high per-
meability’ risk factor on the model behaviours (figure 5). The
effects of the ‘weak stimulus eradication’ risk factor were
assessed through varying the corresponding parameter ( fIP)
from 0.01 (weak stimulus eradication) to 1 (healthy stimulus
eradication; figure 5). Varying fIP for orders of magnitude
higher and lower did not show qualitatively different results.
A.3. Model analysis
½PAR2s and ½KLKs were calculated by solving the fixed
point for algebraic equations of the cellular-level model [22]
using MAPLE v. 13 (Maplesoft, Waterloo, Ontario, Canada).
These were used for the dynamic simulations of the multi-
scale model using the ODE solver ode23t in Matlab v.
R2010a (The MathWorks, Inc., Natick, MA, USA). At each
iteration of the solver, the values of ½PAR2s and ½KLKs
were updated according to the history of S, by using the
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